MedTrace Logo

Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema

NCT01141881 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL

Last updated 2010-10-08

No results posted yet for this study

Summary

Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).

Conditions

Interventions

DRUG

Tissue Plasminogen Activator,bevacizumab ,follow up

25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing

Sponsors & Collaborators

  • Mashhad University of Medical Sciences

    lead OTHER

Principal Investigators

  • naser shoeibi, MD · mashhad university of medical science

Study Design

Purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-01-31
Completion
2010-03-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141881 on ClinicalTrials.gov